Genetic mutations help brain tumors evade targeting by immunotherapy treatments

In a study published this week in the JCI, Hideho Okada’s lab at UCSF investigated whether acquired mutations in the enzyme isocitrate dehydrogenase (IDH), which are common in low-grade gliomas, help these tumors become resistant to immunotherapy. In both human astrocytes and mouse models of glioma, the IDH mutations impaired immune responses in the tumor environment by reducing the recruitment of T cells. …read more

Source: EurekAlert

(Visited 16 times, 1 visits today)

Popular Posts